Cover Image
市場調查報告書

白細胞介素7受體亞單位α:開發中產品分析

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 365742
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
白細胞介素7受體亞單位α:開發中產品分析 Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2017
出版日期: 2017年07月18日 內容資訊: 英文 51 Pages
簡介

本報告提供以白細胞介素7受體亞單位α為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

白細胞介素7受體亞單位α 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Cytheris SA
  • Genexine, Inc.
  • GlaxoSmithKline Plc
  • OSE Immunotherapeutics
  • Pfizer Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0939TDB

Summary:

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Interleukin-7 receptor is a protein found on the surface of cells. It is a receptor for interleukin-7. It acts as a receptor for thymic stromal lymphopoietin (TSLP). It plays an important role in T-cell acute lymphoblastic leukemia, multiple sclerosis, rheumatoid arthritis and juvenile idiopathic arthritis.

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Metabolic Disorders, Central Nervous System, Gastrointestinal, Hematological Disorders and Women's Health which include indications Rheumatoid Arthritis, Type 1 Diabetes (Juvenile Diabetes), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Cervical Intraepithelial Neoplasia (CIN), High-Grade Glioma, Human Papillomavirus Infections, Lymphocytopenia, Multiple Sclerosis, Non-Small Cell Lung Cancer, Sepsis, Sicca Syndrome (Sjogren), Solid Tumor, Transplant Rejection and Ulcerative Colitis.

The latest report Interleukin 7 Receptor Subunit Alpha - Pipeline Review, H2 2017, outlays comprehensive information on the Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R)
  • The report reviews Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Overview
    • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Companies Involved in Therapeutics Development
    • Genexine Inc
    • GlaxoSmithKline Plc
    • OSE Immunotherapeutics
    • Pfizer Inc
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Drug Profiles
    • Antibody to Antagonize IL-7 Receptor Alpha for Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CYT-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2618960 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GX-I7 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OSE-127 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OSE-703 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06342674 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Dormant Products
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Discontinued Products
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 21, 2017: OSE Immunotherapeutics Receives Payment of €2.6 Million from Bpifrance After Completion of a New Key Milestone for its Product OSE-127
      • Jun 15, 2017: OSE Immunotherapeutics Presents Positive Preclinical Results and Human Ex Vivo Data for OSE-127 (Effi-7) to Support Next Clinical Applications in Inflammatory Bowel Diseases at the Federation of Clinical Immunology Societies Conference
      • Jul 22, 2016: Genexine Confirms Possibility of Treatment in Cervicovaginal Tumor with Combination Therapy of hyFc-fused Interleukin-7 and HPV DNA Vaccine
      • Jun 12, 2013: GSK Halts Clinical Trials Of Multiple Sclerosis Drug GSK-2618960 After Fraud Claim
      • Oct 24, 2012: Cytheris Announces US Orphan Drug Designation For CYT107 For Treatment Of Progressive Multifocal Leucoencephalopathy
      • Oct 09, 2012: Cytheris Announces Publication In Blood Demonstrating CYT107 Reverses Lymphopenia And Increases Virus Specific Immunity Post Stem Cell Transplantation
      • Jul 10, 2012: Cytheris Receives European Orphan Drug Designation For CYT107 For Treatment Of Progressive Multifocal Leukoencephalopathy
      • Mar 12, 2012: Cytheris Announces Results Of Phase II Study Indicating That Recombinant Interleukin-7 Expands CD4 T-cells In Gut Mucosa Of Chronically HIV Infected Immunological Non-responder Patients
      • Nov 08, 2011: Cytheris Announces Interim Results From ECLIPSE 2 Hepatitis C Multicenter Study Of IL-7 In Chronically Infected Genotype 1 And 4 Nonresponders To Standard Of Care
      • Oct 26, 2011: Cytheris Presents Interim Data From ECLIPSE 2 Hepatitis C Multicenter Study At AASLD Annual Meeting
      • May 17, 2011: Cytheris And CITN Announce Selection Of Recombinant Interleukin-7 For Initial Studies At Member Institutions
      • May 11, 2011: Cytheris, Lyon And ImmunID Announce Initiation Of Phase IIa Combination Trial Of IL-7 And XELODA In Metastatic Breast Cancer Treatment
      • Mar 01, 2011: Cytheris Announces Results From Phase IIa Study Of CYT107
      • Dec 07, 2010: Cytheris Announces Interim Phase I Study Results Of CYT107 In Treatment Of Post-Transplant Patients
      • Nov 08, 2010: Cytheris' ORVACS Phase II Clinical Study Combines Immunomodulatory Intervention And Antiretroviral Intensification To Attack Viral Reservoir Of HIV Patients
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Genexine Inc, H2 2017
  • Pipeline by GlaxoSmithKline Plc, H2 2017
  • Pipeline by OSE Immunotherapeutics, H2 2017
  • Pipeline by Pfizer Inc, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top